Related Experiment Video
Updated: Jun 3, 2026
08:17
Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis
Published on: February 23, 2024
Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction
1Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Naples, Italy. vdimarzo@icmib.na.cnr.it.
Expert Review of Neurotherapeutics
|April 1, 2011
Summary
The endocannabinoid system, involving compounds like anandamide, plays a role in homeostasis. Modulating this system with Sativex shows promise for treating multiple sclerosis (MS) spasticity.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Endocannabinoids are endogenous agonists of cannabinoid receptors (CB1 and CB2), crucial for maintaining homeostasis.
- Pathological alterations in endocannabinoid levels, such as anandamide and 2-arachidonoyl glycerol, are linked to neurodegenerative diseases and multiple sclerosis (MS).
Purpose of the Study:
- To investigate the therapeutic potential of modulating the endocannabinoid system for disease states.
- To evaluate Sativex (nabiximols), a phytocannabinoid-based treatment, as an endocannabinoid system modulator for MS-related spasticity.
Main Methods:
- Utilized an experimental mouse model of MS-related spasticity.
- Administered Sativex (a 1:1 ratio of tetrahydrocannabinol and cannabidiol) at various dosages.
- Compared Sativex efficacy to baclofen, a standard anti-spasticity treatment.
Main Results:
- Sativex demonstrated dose-dependent improvement in hind limb flexion and stiffness in the MS mouse model.
- A dosage of 10 mg/kg Sativex was found to be as effective as 5 mg/kg baclofen in reducing spasticity.
- These findings suggest Sativex as a promising therapeutic option for MS patients experiencing spasticity.
Conclusions:
- Modulation of the endocannabinoid system holds therapeutic potential for various conditions.
- Sativex is a promising treatment for MS-related spasticity, offering relief for disabling symptoms.
- Further research into the endocannabinoid system may yield treatments for other neurodegenerative, inflammatory, and pain disorders.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...